NCT01441297View on ClinicalTrials.gov

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

March 31, 2016

Conditions
Small Cell Lung CancerSmall Cell Lung Cancer Recurrent
Interventions
DRUG

BIBF 1120

BIBF 1120 200mg bid, PO, daily until PD

Trial Locations (1)

410-769

National Cancer Center, Goyang-si

All Listed Sponsors
collaborator

National Cancer Center, Korea

OTHER_GOV

lead

Ji-youn Han

OTHER_GOV

NCT01441297 - BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter